Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Immunovaccine Inc buy melinda

Start price
€2.74
17.02.17 / 50%
Target price
€4.35
25.04.17
Performance (%)
4.76%
End price
€2.87
25.04.17
Summary
This prediction ended on 25.04.17 with a price of €2.87. The BUY prediction by melinda finished with a performance of 4.76%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Immunovaccine Inc - - - -
iShares Core DAX® -0.383% 5.021% 16.188% 19.224%
iShares Nasdaq 100 1.248% 4.007% 36.579% 57.508%
iShares Nikkei 225® 0.525% -0.109% 12.378% 9.329%
iShares S&P 500 0.640% 3.649% 28.752% 47.932%

Comments by melinda for this prediction

In the thread Immunovaccine Inc diskutieren
Prediction Buy
Perf. (%) 4.76%
Target price 4.352
Change
Ends at 25.04.17

folgen



ImmunoVaccine, Inc. ist ein Impfstoff Unternehmen klinischen Stadium der Entwicklung , die patentierte Impfstoffkandidaten für die Behandlung von Krebs, Infektionskrankheiten DepoVax in der Entwicklung ihrer Vertriebsplattform und Produkt eingreift und Tier health.Its Pipeline Produkte umfasst zwei klinischen Phase - Krebs


Prediction Buy
Perf. (%) 4.76%
Target price 4.352
Change
Ends at 25.04.17

(Vom Mitglied beendet)